Ironwood Pharma (IRWD) Tops Q4 EPS by 6c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance
February 13, 2020 7:00 AM EST2019 revenue of $428 million, driven primarily by U.S. LINZESS® (linaclotide) collaboration revenue
GAAP net income from continuing operations of $59 million and adjusted EBITDA from continuing operations of $148 million for the full year 2019
2020 total revenue and adjusted EBITDA guidance incorporates previously amended agreements with Astellas and AstraZeneca
Data readouts from MD-7246 Phase II trial and IW-3718 Phase III trials expected in 2020
BOSTON--(BUSINESS... More
